NCT05002868 - Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 5, 2021

Primary Completion Date

April 25, 2024

Study Completion Date

April 25, 2024

Conditions

Solid TumorExtensive-stage Small-cell Lung CancerLocally Advanced Breast CancerMetastatic Breast CancerPlatinum-sensitive Ovarian CancerPlatinum-Sensitive Fallopian Tube CarcinomaPlatinum-Sensitive Peritoneal Cancer

Interventions

DRUG

RP12146

starting dose of 100 mg QD

Trial Locations (6)

268 31

Multiscan s.r.o., Hořovice

50 Kopernika Street

SP ZOZ University Hospital in Krakow Oncology Clinic, 50 Kopernika Street, Krakow

93-338

Klinika Onkologii ICZMP, Lodz

Unknown

Pratia Poznań Medical Center, Poznan

Clinical Trials Site Nasz Lekarz, Torun

Maria Skłodowska-Curie Memorial National Oncology Institute, Warsaw

All Listed Sponsors

lead

Rhizen Pharmaceuticals SA

INDUSTRY